The data from several recent monoclonal antibody clinical trials for multiple myeloma (MM), which are producing very exciting results, was…
Browsing: Acute Lymphoblastic Leukemia
The ongoing TOURMALINE-MM1 study (NCT01564537), a Phase III placebo-controlled clinical trial for relapsed refractory multiple myeloma, has produced very positive…
There have been promising preliminary results from the ongoing ASPIRE study (NCT01080391), a Phase III clinical trial for patients with…
Alberto Rocci, MD from the Central Manchester University Hospital, Manchester, UK discusses the encouraging data from recent clinical trials, looking…
Exciting advances in our knowledge of the epigenetics of multiple myeloma (MM) have recently been made. Speaking at the Myeloma…
The highly anticipated panel discussion on the hot topic of MRD at the Myeloma 2017 meeting in Edinburgh, UK produced…
Fantastic advances in immunotherapy, including CAR T-cells, bispecific antibodies and potential immunotherapy combinations, were presented at the Myeloma 2017 meeting…
The current baseline imaging technology for multiple myeloma (MM) management includes PET and MRI. In this interview, Ravi Vij, MD,…
There is currently a conundrum regarding the differentiation of acute myeloid leukemia and myelodysplastic syndromes. In this interview, Stéphane de…
The utilization of CAR T-cells for the treatment of multiple myeloma (MM) has great potential, with numerous different targets and…
Research into imaging for multiple myeloma (MM) is expanding into an exciting new field, which is explored in this discussion…
The mechanisms of therapy resistance in multiple myeloma (MM) are evolving. This is deliberated in this insightful discussion between Marc…
Inhibitors of exportin (XPO1), a nuclear export chaperone, are currently in early clinical trials for acute myeloid leukemia (AML). Speaking…
There are currently several novel agents that target non-coding RNAs being tested in pre-clinical studies for the treatment of leukemia.…
“There are currently a number of ongoing clinical trials for acute myeloid leukemia (AML) that are targeting nuclear exporters. In…
There are four commonly mutated spliceosome proteins in hematological malignancies. In this interesting interview, recorded at the International Conference on…
New molecules targeting specific gene mutations are showing great potential for precisely treating diseases and lowering the toxicity of treatment.…
Having an understanding of the inherited genetic components that can lead to cancer formation can be of great use to…
Holistic therapies are often viewed unfavorably by the medical community, with many clinicians preferring to solely focus on pharmacological treatments.…
Myeloproliferative neoplasms (MPNs) are complex diseases, with current therapies primarily designed to prevent complications and reduce symptoms. In this insightful…
“Technological advances have allowed for whole genome, exome and transcriptome sequencing of circulating multiple myeloma (MM) cells and cell-free tumor…
It has become apparent in recent years that low levels of ciculating tumor DNA can be detected in multiple myeloma…
The detection of various gene mutations, such as those in Ras and Raf, are important for risk stratification and identifying…
The Myeloma 2017 meeting, held in Edinburgh, UK, saw more focus on epigenetic contributors to multiple myeloma (MM) than ever…
In recent years, researchers have become increasingly aware of the fact that epigenetic alterations can contribute to the formation of…
Although researchers are aware of the fact that epigenetic factors play a significant role in the development of multiple myeloma…
There are several different types of immunotherapy and associated conjunctional therapies currently being studied that have shown some degree of…
Cancer immunotherapy is a very active area of research at the moment, with the potential to treat a cancer long-term…
Drug resistance is a common problem in the treatment of multiple myeloma (MM), either through initial resistance to a drug,…
Clinical trials to determine the efficacy of a drug are costly, particularly when there are many subtypes of a certain…
Immunomodulatory drugs (IMiDs) are a class of drugs including the likes of thalidomide, which are used in the treatment of…
Epigenetic modifications, such as DNA methylation, can lead to or complicate disease, and lead to worse patient outcomes. Speaking from…
The Multiple Myeloma Research Foundation (MMRF) is sponsoring the CoMMpass trial (NCT01454297), which aims to define subsets of multiple myeloma…
Speaking from the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH), Stéphane…
The IDH2 inhibitor drug, enasidenib has previously only been administered to elderly populations with acute myeloid leukemia. Stéphane de Botton,…
Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, discusses the efficiency of differentiation therapies for the…
In this video, Stéphane de Botton, MD, PhD of the Gustave Roussy Institute, Villejuif, France, describes the rapid progression of…
The potential advantage of a therapy compared to its cost is an important factor to consider when approving novel treatments.…
The recent RATIFY study (NCT00651261), which led to the approval of midostaurin for the treatment of FLT3-mutated AML patients, was…
When new drugs are being tested as a treatment for a cancer, they are typically trialled in combination with standard…
In the RATIFY clinical trial (NCT00651261), the FLT3 inhibitor midostaurin plus standard chemotherapy was shown to have an advantage over…
The RATIFY trial (NCT00651261) showed that midostaurin, a FLT3 inhibitor that was a previously ineffective monotherapy for acute myeloid leukemia…
Over recent years, inhibition of excessive FLT3 signalling has been a primary area of research to find an effective targeted…
Acute myeloid leukemia (AML) is a complex disease with many subtypes; treatment can be more effective and efficient if there…
The long-term survival rate of acute myeloid leukemia (AML) patients who have relapsed, or whose disease is progressing, is poor.…
Reflecting upon past research is key to the development of new treatments. In this interview at the International Conference of…
Novel technologies have the potential to allow us to treat more ailments, but often come at the price of new…
New and invigorating methods of tackling acute myeloid leukemia (AML) are being researched at present. In this interview, Saar Gill,…
This is an exciting time for leukemia treatment, with multiple new therapies being approved and various agents on the horizon.…
As innovative research investigating acute myeloid leukemia (AML) progresses, the chances of developing effective treatments against the ailment increase. In…